Glucose oxidation in heart-type fatty acid binding protein null mice by Adhikari, Sean
 GLUCOSE OXIDATION IN HEART-TYPE FATTY ACID BINDING  
PROTEIN NULL MICE 
 
 
 
 
A Thesis 
 
by 
 
SEAN ADHIKARI 
 
 
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
MASTER OF SCIENCE 
 
 
 
 
 
 
 
August 2006 
 
 
 
 
 
 
 
Major Subject: Genetics
 GLUCOSE OXIDATION IN HEART-TYPE FATTY ACID BINDING  
PROTEIN NULL MICE 
 
 
 
 
A Thesis 
 
by 
 
SEAN ADHIKARI 
 
 
 
 
Submitted to the Office of Graduate Studies of 
Texas A&M University 
in partial fulfillment of the requirements for the degree of 
 
MASTER OF SCIENCE 
 
 
 
Approved by: 
 
Chair of Committee,  Bert Binas 
Committee Members,  Gale Wagner  
    Jeremy S. Wasser 
    Guoyao Wu 
Head of Genetics Faculty, James R. Wild 
 
 
 
August 2006 
 
 
 
Major Subject: Genetics
 iii
ABSTRACT 
 
Glucose Oxidation in Heart-Type Fatty Acid Binding Protein Null Mice. (August 2006) 
Sean Adhikari, B.S., University of Washington 
Chair of Advisory Committee: Dr. Bert Binas 
 
 Heart-type fatty acid binding protein (H-FABP) is a major fatty acid binding 
factor in skeletal muscles. Genetic lack of H-FABP severely impairs the esterification 
and oxidation of exogenous fatty acids in soleus muscles isolated from chow-fed mice 
(CHOW-solei) and high fat diet-fed mice (HFD-solei), and prevents the HFD-induced 
accumulation of muscle triglycerides. Here, we examined the impact of H-FABP 
deficiency on the relationship between fatty acid utilization and glucose oxidation. 
Glucose oxidation was measured in isolated soleus muscles in the presence or absence of 
1 mM palmitate (simple protocol) or in the absence of fatty acid after preincubation with 
1 mM palmitate (complex protocol). With the simple protocol, the mutation slightly 
reduced glucose oxidation in CHOW-muscles, but markedly increased it in HFD-
muscles; unexpectedly, this pattern was not altered by the addition of palmitate, which 
reduced glucose oxidation in both CHOW- and HFD-solei irrespective of the mutation. In 
the complex protocol, the mutation first inhibited the synthesis and accumulation of 
triglycerides and then their mobilization; with this protocol, the mutation increased 
glucose oxidation in both CHOW- and HFD-solei. We conclude: (i) H-FABP mediates a 
non-acute inhibition of muscle glucose oxidation by fatty acids, likely by enabling both 
the accumulation and mobilization of a critical mass of muscle triglycerides; (ii) H-FABP 
 iv
does not mediate the acute inhibitory effect of extracellular fatty acids on muscle glucose 
oxidation; (iii) H-FABP affects muscle glucose oxidation in opposing ways, with 
inhibition prevailing at high muscle triglyceride contents. 
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INTRODUCTION 
  
History and background 
 The cytosolic Fatty Acid Binding Proteins (FABPs) were discovered in 1972 
[40,44] and are now known to be encoded by a family of homologous genes [50] with 
complex, often overlapping expression patterns [18].  The ligand-binding properties [15] 
and three-dimensional structures [28,16] of many FABPs have been studied; the ability of 
FABPs to promote long chain fatty acid (LCFA) diffusion, sequestration, and transport 
has been demonstrated in cell-free systems [57].  Transfection studies have demonstrated 
the ability of at least some FABPs to affect cellular LCFA uptake, metabolism, lipid 
composition, and LCFA-dependent gene regulation [39,65,66,58,21].  In its entirety, this 
work leads to the hypothesis that FABPs are crucial in mediating and integrating the 
diverse effects of intracellular LCFA and some related compounds.  Testing this 
hypothesis is of obvious clinical interest, since altered fatty acid metabolism and fatty 
acid signaling appear to be central to a number of pathological conditions, most notably 
the metabolic syndrome (e.g., [60,54]).  However, cell-free, transfection, and expression 
studies cannot reveal the quantitative contributions of FABPs to lipid functions in vivo.  
To obtain such information, it is necessary to selectively alter FABP levels or functions 
in the native context, i.e., in vivo or in freshly isolated tissues.  
 Although it might become possible to target FABPs pharmacologically [29], the 
effective and selective manipulation of FABP function in intact tissues currently requires 
genetic means. 
 
__________________ 
This thesis follows the style of American Journal of Physiology – Heart and Circulatory 
Physiology. 
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 One limitation of the genetic approach is that it is inherently slow which  
makes it difficult to distinguish direct/acute from indirect/chronic effects of altered FABP 
levels.  Further, the information that can be gained from the genetic manipulation can be 
limited by the simultaneous expression of a given FABP in several organs, redundant 
expression of different FABPs in the same organ, or compensatory activation of normally 
silent FABP genes.  Indeed, the FABPs are generally expressed rather broadly and with 
redundancy.  Luckily, however, they are expressed differentially and with very little 
overlap or redundancy in those organs that are also the principal contributors to whole 
body fuel metabolism, especially muscle, heart, liver, fat, and gut.  Therefore, genetic 
manipulation of FABPs in these tissues may be expected to create models of regionally 
disturbed lipid metabolism that can be used to study principles of fuel selection, 
interactions between LCFA metabolism and other pathways (especially glucose 
metabolism), pathophysiological roles of regional lipid oversupply, and principles of 
metabolic homeostasis.  It is also worth mentioning that animal models with genetically 
manipulated FABP levels may be directly relevant for human disease, since allelic 
variants of FABP genes appear to modulate human metabolic disease and its treatment 
[64,6]. 
 Several genetic models of altered FABP expression have been created in the last 
few years. Heart-type FABP [3] and keratinocyte-type FABP [19] have been over-
expressed in transgenic mice, and endogenous FABP genes have been inactivated in 
embryonic stem cells that were then used to create “knockout” mice lacking either 
adipocyte-type FABP [22,20], heart-type FABP [4], intestinal FABP [61], keratinocyte-
type FABP [45,35] or liver-type FABP [37,42].  
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 Despite the limitations noted above, the mouse genetics approach has been quite 
useful in illuminating various aspects of FABP biology, as reviewed previously 
[18,13,14,17,36].  The current project describes the fuel-metabolic phenotype of mice 
that lack H-FABP (H-FABP null), a focus that has not previously been made.  This 
FABP-deficient model has three advantages that make it especially attractive for studying 
fuel metabolism: First, the primarily affected tissues (heart and skeletal muscle) play 
major roles in normal whole body fuel metabolism as well as in the development of the 
metabolic syndrome; second, normal FABP expression in these tissues is high yet not 
redundant; third, little or no compensatory increases of other cytosolic fatty acid binding 
proteins appear to occur in these tissues when the original FABPs are deleted.  
Reduced fatty acid binding in H-FABP null cytosols 
 H-FABP was discovered by incubating high speed supernatants (“cytosols”) of 
tissue homogenates with labeled fatty acids, followed by size-exclusion chromatography 
[44,40].  These separations revealed a dominant peak in the 13-15 kDa region, the size of 
the later-purified FABPs.  When cytosols from hearts and soleus muscles [49,5] of H-
FABP null mice were incubated with 3H-palmitate and 3H-oleate, respectively, the 
radioactive peaks in that region essentially disappeared in all cases.  No compensatory 
expression of related FABPs in hearts of H-FABP null mice was detected by northern 
blotting [4,42].  Taken together, the above results demonstrate (i) dominant roles for 
myocellular H-FABP in cytosolic LCFA binding and (ii) lack of adequate compensation 
at the level of the primary defect. 
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Reduced LCFA uptake in H-FABP null 
 The word “uptake” in the literature simply denotes the cellular accumulation of a 
label, including both its movement into the cell and its metabolic fixation.  That is, uptake 
measured over more than a minute usually has a metabolic component, whereas initial 
uptake (measured within seconds) precedes metabolism.  A massively decreased cardiac 
LCFA uptake in resting H-FABP null mice, measured over 30 minutes, was first 
demonstrated with the non-beta-oxidizable but esterifiable fatty acid analog, 125I-BMIPP 
[4].  Also in resting mice and by using a more quantitative method, the cardiac uptakes 
(over 10 minutes) of palmitic acid and arachidonic acid were later found to be decreased 
by 40% and 50%, respectively [41].  Shearer et al. [52] then found that during forced 
(treadmill) physical exercise, the uptake of 125I-BMIPP (over 30 minutes) was reduced 
~12 fold in H-FABP null heart and 4-5 fold in null soleus muscle, as compared to wild 
type controls.  Under this condition, whole body fatty acid utilization was reduced ~4 
fold by the mutation.  In addition, in both organs the fatty acid uptake was linearly 
correlated with the number of H-FABP alleles, i.e., gene dosage (0, 1, and 2).  Cell-free 
experiments with giant vesicles [32] isolated from null skeletal muscles showed that H-
FABP is required for maximal LCFA uptake.  However, in contrast to the in vivo results 
of Shearer et al. [52], uptake by vesicles was not decreased when only one allele was 
deleted.  This discrepancy would suggest that metabolism (that is lacking in the vesicles) 
synergizes with H-FABP in facilitating LCFA transport.  A markedly decreased initial 
uptake of palmitate was also seen in isolated null soleus muscle [5] and cardiomyocytes 
isolated from H-/- hearts [49].  The fatty acid uptake in null mice is strongly suggestive 
of reduced LCFA metabolism.  
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LCFA metabolism and lipid levels in H-FABP null cells 
 Mitochondrial fatty acid oxidation.  Fatty acid oxidation in individual organs 
cannot be easily measured in living mice.  However, it can be measured under near-
physiological conditions in freshly isolated organs and cells.  Palmitate (0.4 mM) 
oxidation was decreased by 45% in H-FABP null vs. wild type cardiomyocyte 
suspensions and was, unlike in wild type cells, not significantly increased by electrical 
stimulation [49].  Resting soleus muscles isolated from null mice also exhibited 
substantial (~70%) decreases of palmitate oxidation at 0.5 mM [5] or 0.1 mM [12] 
palmitate, but unlike in the cardiomyocytes, the “residual” oxidation by null soleus could 
be significantly stimulated electrically [5].  In summary, when tested under conditions 
with a known physiological correlate, H-FABP (muscle, heart) is required in order to 
maintain normal rates of mitochondrial LCFA oxidation in cardiac and skeletal muscle 
cells.  
 Fatty acid esterification and lipid composition.  In resting null vs. wild type mice, 
substantially reduced cardiac incorporation of palmitic acid into neutral lipids but not 
phospholipids was observed, while incorporation of arachidonic acid was reduced in both 
pools [40].  In isolated resting soleus muscle, palmitate incorporation into triglycerides 
and phospholipids was reduced, but in contracting muscles palmitate incorporation into 
phospholipids remained at wild type rates [5].  Overall, in H-FABP null cells, the 
observed reduction of fatty acid esterification into triglycerides was comparable in scale 
with that of uptake (section 3), while rates of phospholipid synthesis were affected less.  
 Based on these facts, it is not surprising that lipid composition of FABP null 
tissues was affected.  These changes are now being studied in detail [42,38,39,41,1]; here 
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we highlight only triglycerides since they are particularly relevant for fuel metabolism.  
Although triglyceride levels in skeletal muscles [5] and cardiomyocytes [49] from chow-
fed mice were not affected by the null mutation, the decrease of triglyceride levels 
observed in wild type soleus muscles upon incubation was blunted in null muscles [5]; 
further, the increase of triglyceride levels in skeletal muscle and heart that occurs 
normally under a chronic high fat diet was prevented in the null mice ([12], and Fig.1).  
Thus, H-FABP facilitates physiological mobilization and deposition of triglycerides, but 
the net effect on the triglyceride levels appear to be sensitive to timing and physiological 
circumstance.  It should also be kept in mind that H-FABP in other organs, such as heart, 
may affect the net accumulation of fat.  
 Taken together, the above results clearly demonstrate that in heart and skeletal 
muscle, H-FABP is an important determinant of LCFA metabolism and lipid 
composition.  In view of the close relationship between lipid and glucose metabolism, 
this predicts that glucose metabolism in H-FABP null mice is also altered.  In fact, the 
prospect of using the null mice for the study of fuel selection was a driving force in 
creating these mice. 
Altered glucose uptake and metabolism in H-FABP null mice  
 A markedly increased cardiac uptake of glucose was first observed in resting null 
mice injected with the non-metabolizable glucose analog, 2-deoxyglucose [4].  These 
experiments were recently confirmed and extended with a more quantitative approach 
that revealed a 6-7 fold increase of cardiac, and a 1.7 fold increase of soleus muscle, 
deoxyglucose uptakes in null versus wild type mice during exercise.  Moreover, 
deoxyglucose uptake in these organs correlated linearly with the number of H-FABP 
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alleles, resulting in a reciprocal pattern of fatty acid and glucose uptakes [52].  In vitro 
experiments with isolated cells and tissue supported these results and added further 
details.  Glucose oxidation in freshly isolated null cardiomyocytes was increased by 
~80% compared to wild type cardiomyocytes but, unlike in wild type cells, was not 
increased by electrical stimulation [49]; it remains to be seen whether this reflects an in 
vitro limitation.  The results with isolated soleus muscles were, in part, surprising. On one 
hand, when measured at physiological insulin levels, the insulin-caused increment of 
deoxyglucose uptake into null soleus muscles from mice fed a standard diet was more 
than doubled as compared to the increment in wild type muscles.  In addition, the 
mutation partially prevented the decrease of insulin responsiveness of deoxyglucose 
uptake seen in wild type soleus muscles isolated from mice subjected to high fat diet [12].  
These two effects are in line with genotypically reduced insulin levels under both diets 
[12] and with the observation (made in a new H-FABP deficient mouse model) that a 
50% reduction of H-FABP levels is sufficient to prevent fat-diet induced hyperglycemia 
[53].  These results demonstrate that H-FABP defines a pool of fatty acids that 
counteracts insulin action.  Moreover, since in vitro, the improved insulin-dependent 
glucose uptakes were seen in the absence of added fatty acid, they were not caused by 
substrate competition, in line with current thinking on fatty acid regulation of insulin 
action [54].  On the other hand, we found that basal (non-insulin-dependent) glucose 
oxidation [5] and deoxyglucose uptake [12] were decreased by ~25-30% in isolated null 
soleus muscle.  The net effect of the mutation, in any case, seems to be increased whole 
body glucose utilization.  This is suggested by decreased glucose levels under resting 
conditions [4,12]; more directly, during exercise whole body glucose usage was increased 
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1.5 fold [52].  Decreased skeletal muscle [5,12] and increased cardiac [49] glycogen 
levels in null mice are consistent with this interpretation and in line with the known fact 
that cardiac and skeletal muscle glycogen contents change in a reciprocal manner [10]. 
Mechanisms of altered fuel metabolism  
 A priori, FABPs may modulate fuel metabolism through primary and secondary 
mechanisms.  The primary effects may be classified by whether they involve interactions 
with other (non-FABP) proteins, and by whether they are exerted on a substrate/product 
or regulatory level.  
 First, in what can be called a “milieu function”, cytosolic FABP levels as high as 
1.2 mM in heart (calculated after [26]), which exceeds the aqueous solubility of LCFA, 
should raise the cytosolic levels and the cytosolic fraction of LCFA. Addition of FABPs 
to membranes indeed increases fatty acid distribution towards the aqueous phase [23,34].  
Further, the equilibrium fraction of LCFA in the aqueous phase correlates with LCFA 
diffusion rate [34], and LCFA transport in membrane model systems is stimulated by 
addition of FABPs [56].  Thus, FABPs may increase the cytoplasmic levels, fractions, 
and diffusional mobilities of LCFA and LCFA-CoA without contacting other proteins.  
As a result, the availability of LCFA/LCFA-CoA as substrates and their removal (if they 
are products) may be facilitated by the milieu function (Fig. 2A).  Deletion of these 
functions in FABP null tissues would be expected to reduce rates of LCFA diffusion and 
metabolism, which is in line with the observed reductions of LCFA oxidation, 
esterification, and ester hydrolysis (sections 2-5).  In addition, as illustrated in Fig. 2B, 
the milieu function could determine the availability of FABP ligands for regulatory 
proteins that sense unbound fatty acid levels.  In this case, the effects of FABP deletion 
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may be more difficult to predict, but one might surmise that impaired fatty acid sensing 
would trigger attempts to re-establish cellular fatty acid homeostasis.  
 A second type of primary FABP effects, which may be called “targeting”, could 
derive from physical interactions between FABPs and other proteins.  Again, these 
interactions might modulate the availability of FABP ligands for enzymatic conversion 
(Fig. 2A) or fatty acid sensing (Fig. 2B).  The best-documented specific interaction of a 
non-FABP with H-FABP concerns the PPAR transcription factor family, in which 
transfected H-FABP was shown to activate PPAR-alpha [57] although physical contact 
was not demonstrated.  Since PPAR-alpha is required for a high LCFA-oxidative 
capacity of heart [63], the activation by H-FABP would predict a reduced capacity for 
LCFA oxidation in H-FABP null cells.  However, at least under physiological conditions 
that favor high rates of LCFA oxidation, PPAR-alpha-dependent transcription, or 
generally transcription of genes relevant for LCFA oxidation, does not appear to be 
altered in null hearts.  This is suggested by the findings that the levels of PPAR-alpha-
dependent mRNAs as well as the oxidation of albumin-bound LCFAs remained normal in 
homogenates of null hearts [11,4,49,42].  Furthermore, oxidation of the medium chain 
fatty acid octanoate (that is not bound by FABPs) remained normal in null 
cardiomyocytes, while it was reduced in PPAR-alpha-/- hearts [63,31,11].  
 In addition to the demonstrated effects on LCFA oxidation and esterification, 
further primary effects (via milieu and/or targeting) of H-FABP on fuel metabolism may 
be predicted from the literature.  For example, hexokinase is inhibited by LCFA [56], 
glucose-6-phosphatase is inhibited by polyunsaturated fatty acids [9], and glucokinase 
[59] and acetyl CoA carboxylase [43] are inhibited by LCFA-CoA.  Assuming that H-
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FABP facilitates the availability of these lipids, we would expect in FABP null, as 
compared to wild type cells, increased rates of glycolysis, glycogen synthesis, lipogenesis 
and (in a PUFA-rich environment) gluconeogenesis.  These predictions remain all to be 
tested. 
 Secondary effects of H-FABP on fuel metabolism may act in similar ways as the 
primary effects (notably, a secondary reduction of LCFA-CoA would affect its 
availability) or in qualitatively new ways.  For example, LCFA oxidation is known to 
increase gluconeogenesis [27,62] and reduce glycolysis [47] through several mechanisms 
involving metabolites such as acetyl CoA, NADH, xylulose-6-phosphate, and citrate.  
Therefore, one can expect that the reduced LCFA oxidation increases glycolysis in FABP 
null muscle and heart.  Further, accumulation of LCFA esters has been linked with 
insulin resistance in skeletal muscle [54].  Therefore, one can expect improved insulin 
action in FABP null tissues under high fat diet; as indeed observed in H-FABP (see 
section 5).  In contrast, the situation is less predictable during normal diet when lipid 
levels are not much changed by the mutation, although insulin action was improved under 
this condition as well [12].  
Present study of glucose metabolism in H-FABP null muscles 
 
 The present study focuses on the question of whether and how H-FABP affects 
skeletal muscle glucose oxidation.  In freshly isolated cardiac muscle cells, genetic H-
FABP deficiency has been shown to markedly decrease fatty acid oxidation, and at the 
same time, glucose oxidation was markedly increased [49].  Since glucose and fatty acid 
are, within limits, interchangeable fuels, we have interpreted the increased glucose 
oxidation as a compensation that avoids fuel shortage.  Using isolated skeletal muscles, 
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we later found that just like H-FABP deficient isolated cardiomyocytes, H-FABP 
deficient isolated skeletal muscles show a pronounced decrease of fatty acid oxidation [5, 
12]. Unlike in cardiomyocytes, however, increased glucose oxidation was not observed in 
H-FABP deficient skeletal muscles; in fact, glucose oxidation was even slightly reduced, 
regardless of whether the muscles were resting or stimulated electrically to contract [5]. 
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OBJECTIVES 
 The present study was inspired by the belief that regardless of the paradoxical 
decrease of basal glucose oxidation in H-FABP null soleus muscles [12], fatty acids can 
antagonize skeletal muscle glucose oxidation in wild-type muscles under more 
appropriate conditions.  In view of the markedly reduced plasma glucose level of H-
FABP deficient mice [4, 12], we surmised that the lack of increased skeletal muscle 
glucose oxidation results from some systemic fuel-sparing mechanism favoring cardiac 
over skeletal muscle needs, rather than from the relief of intramuscular effects of fatty 
acids on muscle glucose oxidation.  We therefore felt that in a more appropriate 
experimental protocol, H-FABP may still mediate local, antagonistic effects of fatty acids 
on muscle glucose oxidation, as required by the concept of the glucose-fatty acid cycle 
[47].  Thus, at the outset of this project, our central hypothesis was that because it impairs 
muscle fatty acid oxidation, H-FABP deficiency stimulates muscle glucose oxidation in 
all situations when fatty acids are normally oxidized.  More specifically, we distinguish 
here two situations.  After their uptake by muscle cells, fatty acids that are initially 
present in the medium are either immediately oxidized or first esterified; in the latter 
case, there will be a time delay that may extend beyond the actual presence of fatty acids 
in the medium.  Accordingly, the present project studied the impact of H-FABP 
deficiency both on the acute effect of fatty acid on muscle glucose oxidation and the 
impact of H-FABP deficiency on muscle glucose oxidation in situations when 
intramuscular triglycerides are mobilized for oxidation.  Accordingly, we can reformulate 
the above hypothesis for each of these situations as follows: 
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Hypothesis 1: The acute effect of exogenous fatty acids on muscle glucose oxidation 
is impaired or abolished in H-FABP deficient muscles. 
 To test this hypothesis, we incubated soleus muscles from wild type and H-FABP 
null mice in the presence and absence of 1mM palmitate, a fatty acid concentration at 
which hydrolysis of triglycerides is minimal.  Since according to Randle [47], fatty acid 
oxidation impairs glycolysis and glucose uptake, we measured not only glucose 
oxidation, but also glycolysis, glucose uptake, and glycogen synthesis. 
Hypothesis 2: H-FABP deficiency impairs the mobilization of muscle triglycerides 
and consequently ameliorates the inhibitory effect of endogenous fatty acids on 
glucose oxidation. 
 To test this hypothesis, we analyzed soleus muscles from wild type and H-FABP 
null mice that were subjected to two treatments.  First, mice were fed a high fat diet 
(HFD) for four weeks and then their soleus muscles were isolated and assayed for 
glucose oxidation.  Our laboratory has previously shown that HFD increases muscle 
triglyceride levels, and that this increase is prevented by H-FABP deficiency [12].  Thus, 
muscles from HFD-fed H-FABP null mice cannot mobilize as much triglyceride for 
oxidation as wild type muscle, regardless of any effect of H-FABP deficiency on 
triglyceride mobilization itself.  Second, we aimed to increase triglyceride levels in vitro 
by incubation with 1 mM palmitate, which was followed by a measurement of glucose 
oxdidation in the absence of fatty acid, which maximizes triglyceride hydrolysis. 
 In order to assess triglyceride degradation, one muscle from each pair per animal 
was removed and shock frozen before and after incubation in the final step, and 
triglycerides were measured using an enzymatic method or a thin layer chromatography 
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approach (TLC).  In order to demonstrate the oxidation of internal triglycerides, 3H-
palmitic acid was present in the first step, non-incorporated 3H-palmitic acid was washed 
out in the second step, and triglyceride oxidation was measured from the release of 
tritiated water in the final step.  In parallel, 14C-glucose was present in the final step in 
order to measure glucose oxidation. 
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MATERIALS AND METHODS 
 
Animals 
 
 An animal use protocol (AUP) was approved by the University Laboratory 
Animal Care Committee (ULACC) of Texas A&M University.  For anesthesia, mice 
were injected with 1.2% tribromoethanol (Avertin) at 20 µL/g body weight before 
sacrifice.  All mice used in this study were male or female strain C57BL/6, between ages 
3-5 months old.  Mice were either null, heterozygous, or wild-type for the H-FABP gene 
locus in a genetically fixed background.  Mice received a standard chow (no. 8604, 
Harlan Teklad) or a high-fat diet [no. TD 93075, Harlan Teklad; main digestibles in g/kg: 
289 protein, 207 starch, 90 sucrose, 274 shortening (Primex), 16 cellulose] for 4 wk, 
transported to the lab on the previous day before the experiment, and sacrificed the 
following morning. 
 
Preparation of BSA with fatty acids [33] 
 
 To make a stock solution of 125 mM palmitic acid, 801mg of palmitic acid was 
dissolved to a final volume of 25 mL absolute ethanol, by slight warming and 
periodically vortexing.  For the control without fatty acids, absolute ethanol was used.  
Into 15 mL polypropylene tubes, 4 mL 37.5 mM KCl was added for the control and 4 mL 
37.5 mM KOH was added for the palmitic acid solution.  Into the KCl, 0.8 mL absolute 
ethanol was added and into the KOH, 0.8 mL ethanol with 125 mM palmitic acid was 
added to make potassium palmitate (K-palmitate) and both were mixed.  The ethanol was 
evaporated from each tube by gassing with N2 for 30 minutes and occasionally vortexing 
during evaporation. 
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Meanwhile, 20% fatty acid-free bovine serum albumin (BSA) was prepared by 
dissolving 10 grams fatty acid-free BSA in distilled water to a final volume of 50 mL.  
After the volumes of the KCl and KOH were 4 mL each again, 4 mL of the KCl was 
added to 16 mL 20% BSA to make control BSA and 4 mL K-palmitate was added 
dropwise to 16 mL 20% BSA in a beaker under constant warming and stirring with a 
Teflon stirring bar to make 5 mM K-palmitate in BSA.  Both the control and K-palmitate 
were aliquotted into 1.5 mL Epindorff tubes and stored at -20°C. 
 
Measurement of fatty acid oxidation [12] 
 
Incubations for each muscle or pair of muscles were performed under constant 
gassing with carbogen (95% O2 and 5% CO2) in Krebs-Henseleit-Buffer (119 mM NaCl2, 
4.8 mM KCl, 1.2 mM KH2PO4, 2.5 mM CaCl2, 1.2 mM MgCl2, and 25 mM NaHCO3) 
supplemented with 5 mM glucose, 4% bovine serum albumin (fatty-acid free), 0.1 mM or 
1 mM palmitic acid, and 1 uCi/mL tritiated palmitic acid as a radioactive tracer.  Mice 
were anesthetized with avertin (2,2,2 tribromoethanol, Fluka cat. No. 90710), and solei 
from the hind limbs were rapidly removed and immersed into 1.5 mL of the media under 
constant gassing for 1 hour.  After incubation, solei were blotted on paper, trimmed, 
weighed, and shock frozen for esterification analysis. 
 Oxidation was measured by output of tritiated water, the by-product of fatty acid 
oxidation.  1 mL of media was extracted with 5 mL of 2:1 chloroform-methanol, acidified 
with 2M KCl/HCl, centrifuged, and an aliquot of the upper aqueous phase was counted in 
Fisher Scintiverse scintillation liquid. 
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Example (For 3 mice and 1 blank, 1.5 mL each = 6 mL, so make 7 mL to avoid pipetting 
losses): 
• Prewarm shaking water bath to 30°C. 
• Combine 4.6 mL water, 0.7 mL 10x KHB, 0.196 mL 7.5% NaHCO3, and 35 uL 
1M glucose in a 15 mL polypropylene tube. 
• Gas (by bubbling) with a Pasteur pipette for 15 minutes with carbogen. 
• Add 70 uL 250 mM CaCl2 and 1.4 mL 20% BSA with palmitic acid (see 
Preparation of BSA with fatty acids).  Add 7 uL 3H-palmitic acid from Moravek, 
to make 1 uCi/mL. 
• Mix well and distribute 1.5 mL aliquots of media to 20 mL scintillation vials. 
• Begin gassing and shaking vials at least 10 minutes before incubation. 
• Inject each mouse with avertin (0.5 mL/25 g body weight) and use 8 minute 
intervals between incubations.  After anesthesia, rapidly remove solei from hind 
limbs and immerse into vial containing 1.5 mL prewarmed and pregassed 
solution. 
• After 60 minutes incubation, remove muscles from solution, blot on paper, trim, 
weigh, and shock freeze for esterification analysis. 
• Aliquot 5 mL of 2:1 chloroform:methanol solution into 15 mL polypropylene 
tubes. 
• Aliquot 1 mL of blank and each sample of media in which muscles were 
incubated into each tube containing chloroform:methanol. 
• Vortex and shake each tube on rotating shaker for 10 minutes. 
• Add 2 mL 2M HCl/KCl to each tube, vortex, and shake for another 10 minutes. 
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• Centrifuge tubes at 3000 rpm for 5 minutes. 
• Aliquot 0.5 mL of aqueous (upper) phase in duplicates into 7 mL scintillation 
vials and add 5 mL scintillation cocktail.  Shake well and count for 5 minutes 
each. 
 
Measurement of 3H-triglyceride and phospholipid content [12] 
 
 Muscles were homogenized using a Wheaton glass homogenizer in 1mL 1:1 
chloroform-methanol, aliquotted into 1.5 mL tubes, and centrifuged at 2000 rpm at 4°C 
for 10 minutes.  The supernatant was then transferred to a new tube, 0.4 mL water was 
added, and the tubes were shaken for 10 minutes.  After centrifugation again under the 
same conditions, the lower organic phase was transferred with a Pasteur pipette to a new 
tube and evaporated with N2 air.  The remaining lipid was then redissolved in 100 µL 2:1 
chloroform-methanol and 20 µL of each sample was spotted on an oven-dried silica gel 
plate for thin layer chromatography (TLC) analysis.  The silica plates were placed in a 
closed container with a 60:40:3 heptane-isopropyl ether-acetic acid solution with the fluid 
level just below the spots, allowing bands of triglycerides and phospholipids to rise to the 
top.  The bands were then scraped into 20mL scintillation vials and counted in 4 mL 
Fisher ScintiSafe scintillation liquid per vial. 
 
Measurement of glucose uptake [12] 
 
 The same conditions as the measurement of fatty acid oxidation were used, except 
that three different incubation media were used in order to measure glucose uptake, in the 
following order: 
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Solution 1: Krebs-Henseleit buffer (KHB) with 8 mM glucose and 32 mM 
mannitol, incubated 40 minutes 
 Solution 2: KHB with 40 mM mannitol, incubated 10 minutes 
Solution 3: KHB with 1 mM 2-deoxy-glucose, 39 mM mannitol, and 1 µCi/mL 3-
H labeled 2-deoxy-glucose, incubated 20 minutes 
 4% fatty acid-free bovine serum albumin (BSA) was present throughout all 
incubations, as well as 1 mM palmitic acid, for those muscles incubated in the presence 
of fatty-acids.  Each mouse was anesthetized with Avertin, solei were rapidly removed, 
one muscle was incubated in media solely containing the above reagents, and the other 
muscle was incubated in media containing the above reagents supplemented with either 1 
mM palmitic acid, 2 mU/mL insulin (Humulin R), 2 mM AICAR, 0.5 mM 2,4-
dinitrophenol (DNP), or a combination of these. 
 After incubation, muscles were blotted on paper, trimmed, weighed, and dissolved 
in 1M KOH.  After neutralization with an equal volume of 1M HCl, aliquots were 
counted in Fisher ScintiVerse scintillation liquid to measure total deoxy-glucose uptake. 
Example (for 3 mice = 6 muscles, 1.5 mL per muscle, 9 mL per solution = 27 mL, 30 mL 
was prepared): 
• Combine 19.86 mL water, 3 mL 10x KHB, and 0.84 mL 7.5% NaHCO3 and mix 
well. 
• Gas (by bubbling) with a Pasteur pipette for 15 minutes with carbogen. 
• Add 0.3 mL 250 mM CaCl2 and mix well. 
• Split solution into 2 aliquots of 12 mL each and add 3 mL control BSA to one and 
3 mL BSA with K-palmitate to the other (total 15 mL each). 
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• Aliquot 5 mL control solution each into 3 tubes (1a, 2a, 3a) and aliquot 5 mL K-
palmitate solution each into 3 tubes (1b, 2b, 3b). 
• Into tube 1a, add 40 µL 1M glucose and 0.32 mL 0.5M mannitol, and add the 
same to 1b. 
• Into tube 2a, add 0.4 mL 0.5M mannitol, and add the same to 2b. 
• Into tube 3a, add 0.39 mL 0.5M mannitol, 50 µL 0.1M 2-deoxy-glucose, 7.5 µCi 
(7.5 µL) 3H-2DG, and 1.5 µCi (15 µL) 14C-mannitol, and add the same to 3b. 
• Mix all tubes well.  Aliquot 1.5 mL each of solution 1 into a set of vials, and do 
the same for the other solutions.  Place racks in shaking bath and gas for 10 
minutes before incubation. 
• Inject each mouse with avertin (0.5 mL/25 g body weight) and use 8 minute 
intervals between incubations.  After anesthesia, rapidly remove solei from hind 
limbs and immerse one muscle into vial containing 1.5 mL prewarmed and 
pregassed fatty-acid free media, and the other muscle into media with 1 mM 
palmitic acid. 
• Incubate all muscles in solutions 1, 2, and 3 for 40, 10, and 20 minutes, 
respectively. 
• After incubation, remove each muscle, blot on paper, trim, weigh, and place in 1.5 
mL Epindorff tube. 
• Add 0.5 mL 1M KOH to each tube and dissolve muscles by heating at 80°C for 
30 minutes.  Vortex each tube and neutralize by adding 0.5 mL 1M KCl and 
mixing. 
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• Aliquot 0.3 mL in duplicates into 7 mL scintillation vials and count in 5 mL 
scintillation liquid. 
 
Measurement of glucose utilization 
 
 The same conditions as the measurement of fatty acid oxidation and glucose 
uptake were used, except that the measurement of glucose utilization involved only a 
two-step incubation procedure, and that Krebs-Henseleit buffer (KHB) was supplemented 
with 10 mM HEPES acid for all incubations.  Muscles were pre-incubated for 30 minutes 
in a wash solution containing Krebs-Henseleit buffer (KHB) with 5 mM glucose, 
followed by a 90-minute incubation in a second medium containing the same reagents, 
plus 0.5 µCi/mL 14-C glucose and 1 µCi/mL 3-H glucose.  For each animal, one muscle 
was incubated in media containing solely the reagents just stated, and the other muscle 
was incubated in media containing the reagents plus either 1 mM palmitic acid, 2 mU/mL 
insulin, 2 mM AICAR, 0.5 mM 2,4-dinitrophenol (DNP), or a combination of these.  
After the muscles were placed in the incubation medium, they were gassed for 1-2 
minutes and sealed with a rubber septum during the 90-minute incubation period.  At the 
end of the incubation, the vials were placed on ice for 5 minutes, the muscles were 
removed and shock frozen, a tube containing 1M KOH was placed in the vial, the vial 
was sealed again with a rubber septum, and perchloric acid was injected into the media to 
liberate the 14-C CO2.  After a 90-minute collection period, aliquots of the KOH were 
counted for 14-C CO2 content in Fisher ScintiVerse scintillation liquid, in order to 
measure glucose oxidation. 
 Glycolysis was measured by placing an open tube with 0.5 mL non-radioactive 
water in vials with metabolized media, sealing the vials, and incubating them at 37°C for 
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72 hours.  This allowed the separation of tritiated water, the by-product of glycolysis, 
from tritiated glucose, as the tritiated water came into equilibrium with the non-
radioactive water in the tube.  Duplicate aliquots of 0.15 mL were then counted in 5 mL 
scintillation liquid. 
 Glycogen synthesis was measured by adding 0.2 mL 30% KOH to each Epindorff 
tube containing a muscle (~10 mg) and incubating them at 97°C for 15 minutes.  
Afterwards, 20 µL of glycogen (25 g/L) and 1 mL cold ethanol was added, and the 
samples were incubated at -20°C overnight to allow precipitation of glycogen.  The 
samples were then centrifuged at 10,000 rcf at 4°C for 5 minutes, the supernatant was 
aspirated and discarded, and the pellet was washed twice by the addition of cold ethanol, 
centrifugation, and removal of the supernatant as just described.  The pellet was then 
dried by heating at 97°C for 1-2 minutes, cooled, and then re-dissolved in 0.6 mL water.  
Aliquots of 0.25 mL in duplicates were then counted in 5 mL scintillation liquid for 14-C 
glycogen content. 
 
Measurement of pyruvate dehydrogenase (PDH) activity [55] 
 
The following solutions (stored in 1 mL aliquots at -20°C) were used in the 
measurement of the total (both non-phosphorylated and phosphorylated form) and actual 
(phosphorylated) PDH activity: 
Homogenization buffer: 250 mM sucrose, 2 mM EDTA, 10 mM Tris-HCl pH 7.4, 
50 U/mL Heparin; added freshly: 0.1 mM PMSF 
Assay cocktail 1: 100 mM Tris, 0.5 mM EDTA, 2 mM MgCl2, 0.5 mM NAD+, 1 
mM TPP, 2 mM CoA, 0.08 mM Cytochrome C, 5 mM L-carnitine pH 7.4; Added 
freshly: 10 µL/mL NADHCR 
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Assay cocktail 2: Same as Solution 1, except containing 2 mM Ca and 4 mM Mg 
The following procedure was used for the assay: 
 
• Preheat shaking water bath at 37C. 
• Add 10 µL NADHCR suspension to both tubes of assay cocktail solutions. 
• Add 20 µL 100 mM CaCl2 and 3.33 mL 600 mM MgCl2 to one of the assay 
cocktail solutions to make assay cocktail 2, which will be used in the 
measurement of the total PDH activity. 
• Add 0.4 mL of each assay cocktail to 20 mL scintillation vials and place in water 
bath.  Place 2 mL Epindorff tubes with lids cut off with 0.5 mL 1M KOH in vials. 
• Add 1 µL 0.1M PMSF to homogenization buffer to make 0.1 mM PMSF. 
• Weigh and grind tissues with pestle over liquid nitrogen. 
• Homogenize with homogenization buffer at 20% w/v. 
• Aliquot homogenized tissues into Epindorff tubes.  Freeze in liquid N2 and thaw 
for 3 cycles. 
• For total activity, add 50 µL homogenate to assay cocktail 2 and preincubate for 
10 min at 37C before starting the reaction.  Meanwhile, place homogenate stock 
on ice and add 50 µL to assay 1 for actual activity upon starting incubation. 
• Upon starting the reaction, add 50 µL radioactive pyruvate to reaction, seal with 
rubber septum, and incubate for 20 minutes.  After 20 minutes, inject 0.2 mL 3M 
Perchloric acid into the assay cocktail to stop the reaction and liberate the 14CO2. 
• Shake for 90 minutes to collect 14CO2 in the KOH and then count 0.2 mL aliquots 
in duplicates in 5 mL scintillation vials. 
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Measurement of internal triglyceride oxidation 
 
 For the measurement of internal triglyceride oxidation, the same conditions and 
solutions as the measurement of glucose utilization were used, except that three separate 
phases were used during incubation, each for 1 hour: 
Step 1 (Pulse): Incuabation in KHB with 5 mM glucose, 1mM palmitic acid, and 
5 µCi/mL 3-H palmitic acid in order to label internal triglycerides 
Step 2 (Wash): Incubation in KHB with 5 mM glucose and 1 mM palmitic acid 
without radioactivity, to wash out non-incorporated labeled fatty-acids 
Step 3 (Chase): Incubation in KHB with 5 mM glucose, without fatty-acids, in 
order to ensure that only internal triglycerides are used for fatty-acid oxidation 
 For each animal, a pair of muscles were incubated with a quick rinse (~30 sec) 
before and after each phase.  The first rinse was to remove excess blood before labeling, 
the second rinse before the wash phase prevented excess radioactive solution from being 
carried over by the muscle, and the third rinse prevented excess fatty acids from being 
carried over into the Chase phase.  From each pair, one muscle was removed before and 
after the Chase phase, blotted on paper, trimmed, weighed, and shock frozen in order to 
analyze triglyceride degradation, by means of TLC analysis using the “Measurement of 
radiolabeled triglyceride content” method [12].  Triglyceride oxidation was measured in 
the vials from the Chase phase by measuring the output of tritiated water, using the 
extraction method under “Measurement of fatty acid oxidation.” 
 
Measurement of total internal triglyceride content [32] 
 
Frozen soleus muscle tissue (~10 mg) was placed in a glass homogenizer and 
homogenized with 0.5 mL 4:1 chloroform:methanol.  The homogenate was transferred to 
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a round bottom 2 mL tube and shaken for 3-4 hours at 22°C.  Afterwards, phases were 
separated by adding 0.2 mL 1M H2SO4 and vortexing.  For the blank reaction, 0.5 mL 4:1 
chloroform:methanol was simply combined with 0.2 mL 1M H2SO4 and processed the 
same way as the other samples.  The tubes were then centrifuged at 1,000 rpm for 10 
minutes at room temperature and the bottom organic phase (~0.2 mL) was transferred to 
a new tube.  The organic phase was evaporated with N2 and the remaining triglyceride 
was re-dissolved in 40 µL isopropanol.  Triglyceride reagents from Wako Diagnostics 
were used for the quantification of triglyceride content.  0.26 mL of Reagent R1 was 
mixed with 3 µL of the sample and incubated at 37°C for 5 minutes.  0.13 mL of Reagent 
R2 was added and mixed with the reaction and incubated at 37°C for another 5 minutes.  
The reaction mixture was then transferred to a 0.6 mL ultraviolet (UV) cuvette and the 
absorbance was measured at OD 600nm with a reference wavelength set at 700nm.  The 
differences in OD readings were then normalized to muscle weight. 
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RESULTS 
 
External fatty acid oxidation and esterification 
 
In order to determine the conditions of the greatest genotypic difference with 
respect to fatty acid oxidation, we developed a gene dosage curve of exogenous fatty acid 
oxidation, using null, heterozygous, and wild-type mice in each experiment, in the 
presence of 0.15 mM or 1.5 mM palmitic acid (Figure 1).  The greatest genotypic 
difference was observed at 1.5 mM palmitic acid, therefore we used this concentration in 
all subsequent experiments.  Previously, fatty acid utilization in vivo in exercising mice 
was assessed, and a strictly linear relationship was demonstrated among genotypes to 
demonstrate the gene dosage effect [52].  In other words, the heterozygous genotype (+/-) 
was exactly midway between knockouts and wild-types in terms of ability to oxidize fatty 
acids.  Oxidation was also assessed by means of vesicle transport [32], and the 
relationship was found to be strictly qualitative (the heterozygote performs at the same 
level as the homozygous wild-type).  We wanted to verify which model was correct by 
using the isolated muscle incubation method.  At 0.1 mM palmitic acid, the relationship 
was neither strictly linear nor was the heterozygote the same as true-breeding wild-type, 
but the relationship indicated a “bent” curve.  In other words, the presence of one gene 
allows performance up to 60-70%, compared with normal physiological conditions.  At 1 
mM palmitic acid, the relationship appeared more linear, as the heterozygote performed 
at 50-60% of the wild-type.  With respect to triglyceride synthesis, there was no 
significant difference between heterozygous and wild-type muscles. 
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Figure 1.  Palmitate oxidation.  Oxidation was measured at 0.15 mM (A) and 1.5 mM (B) 
palmitate and triglyceride synthesis at 0.15 mM (C) and 1.5 mM (D) palmitate with H-
FABP null (-/-), heterozygous (+/-) and wild-type (+/+) mice.  Each point represents 5-6 
muscles from male mice studied in 5-6 independent experiments.  Significant differences 
were observed between null and wild-type (*) and between heterozygous and wild-type 
(+) with double symbols representing P<0.01 and triple symbols representing P<0.001.
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Measurement of 2-deoxy-glucose uptake into soleus muscle 
 
We have previously assessed glucose uptake in the absence of fatty acids [12] 
after standard chow and high-fat diets.  As a result, we have shown that insulin-
independent (basal) glucose uptake was moderately reduced in the null muscle regardless 
of the diet, whereas no significant genotypic difference existed in the presence of 2 
mU/mL insulin after standard chow diet.  In contrast, insulin-dependent glucose uptake 
was significantly decreased in wild-type muscles after high-fat diet (HFD) in the presence 
of 2mU/mL of insulin, indicating a non-acute effect of the diet, which was absent in the 
null phenotype.  Hence, glucose uptake in the null muscle at 2 mU/mL insulin was 
considerably higher than wild-type after HFD. 
Next, we wondered whether or not the acute presence of fatty acids would affect 
the genotypic pattern in the absence and presence of insulin (Figure 2).  In order to 
determine whether or not the previously described Randle cycle applied to the situation 
of the null muscle, we incubated pairs of knockout and wild-type muscles from each 
animal, one in the absence and one in the presence of 1 mM palmitic acid.  Surprisingly, 
in both the absence and presence of insulin, palmitic acid suppressed glucose uptake in 
the null muscle to the same extent as in the wild-type. 
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Figure 2.  2-deoxyglucose uptake.  Soleus muscles are from wild-type (+/+) and null (-/-) 
mice without and with insulin in the absence and presence of 1 mM palmitate.  Open bars 
represent muscles incubated without fatty acids and closed bars represent incubation in 
the presence of palmitate.  Each column represents 5-7 muscles from female mice studied 
in 3-4 independent experiments.  Significant differences were observed between absence 
and presence of palmitate (*), between genotypes (+), and between absence and presence 
of insulin (#) with single symbols representing P<0.05, double P<0.01, and triple 
P<0.001. 
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Measurement of glucose oxidation 
 
We measured glucose oxidation in order to determine whether or not the patterns 
observed in glucose uptake were the same as oxidation (Figure 3).  As with glucose 
uptake, we examined the acute effect of fatty acids, and found that palmitic acid inhibited 
glucose oxidation in both null and wild-type muscles to the same extent, regardless of 
whether or not insulin was present.  We wondered whether or not the same genotypic 
patterns in the absence and presence of palmitate would be observed after a 4-week high-
fat diet (HFD) feeding.  After HFD, the genotypic pattern between wild-type and H-
FABP null muscles was now completely different.  Both in the absence and presence of 
insulin, glucose oxidation was considerably increased in the null muscle, compared to the 
wild-type.  However, what remained similar to the observations with chow fed mice was 
that the acute addition of 1 mM palmitate reduced glucose oxidation in both wild-type 
and null muscles to a comparable degree, arguing that some non-acute effect of the diet 
causes the genotypic change in glucose oxidation. 
 In order to understand the nature of this change in genotypic pattern, we clarified 
whether this change was due to an increase in oxidation of the null or rather a decrease in 
the wild-type.  In each incubation, a mouse fed standard chow was used for each 
genotype as a control in order to observe the changes between the diets.  We observed 
that the high-fat diet caused a dramatic decline in glucose oxidation of the wild-type, 
which was prevented in the null.  Since we have previously shown that HFD caused a 
dramatic accumulation of triglycerides in the wild-type, but not the null, we wondered 
whether or not internal triglycerides would play a role in counteracting glucose oxidation. 
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Figure 3.  Glucose oxidation.  The effect of H-FABP deficiency on glucose oxidation 
depends on diet, but not on the acute presence of fatty acids.  Soleus muscles were 
isolated from wild-type or null mice fed standard chow (A), high-fat (B), or both in 
parallel (C).  Muscles were incubated with or without 1 mM palmitate.  Each column 
represents muscles from 5-10 mice studied in 3-5 independent experiments.  
Comparisons were made between genotypes (*), between absence or presence of 
palmitate (#), and between diets (+).  Single symbols (*, #) indicate P<0.05 and double 
symbols (**, ++) indicate P<0.01. 
 
 32
Measurement of endogenous triglyceride mobilization 
 
 After observing the changes in glucose oxidation between standard and high-fat 
diets, we investigated whether or not the synthesis and degradation of intramyocellular 
triglycerides were altered between wild-type and null muscles (Figure 4).  Previously, it 
has been demonstrated that no difference exists in triglyceride levels between freshly 
isolated knockout and wild-type muscles and that the H-FABP null muscle exhibits 
impaired degradation of triglycerides [5].  It has also been shown that after HFD in 
freshly isolated muscles, wild-type muscles have accumulated enormously large levels of 
triglycerides, whereas this was prevented in the knockout [12].  Therefore, after HFD, 
wild-type muscles had considerably higher levels of triglycerides than the null muscles.  
We hypothesized that this was the explanation for the altered pattern of glucose 
oxidation, as if wild-type muscles contain higher triglyceride levels and if those 
triglycerides are degraded and oxidized at a greater rate, the Randle effect would occur at 
a greater intensity, and would inhibit glucose oxidation in the wild-type, but not the 
knockout.  The first method to measure triglyceride levels involved enzymatic reactions, 
using reagents supplied by the manufacturer to measure total triglyceride levels.  The 
second was a Pulse-Chase method, in which 3H-palmitate was used as a radioactive 
tracer in order to demonstrate the synthesis and breakdown of triglycerides, after isolation 
from thin layer chromatography (TLC).  Using both methods, we demonstrated that both 
triglyceride synthesis and degradation occurred rapidly in the wild-type, but were 
impaired in the knockout. 
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Figure 4.  Triglyceride synthesis and degradation.  Muscles are from mice fed standard 
chow (A, B) and high-fat diet (C, D), using enzymatic (A, C) and radioactive TLC (B, D) 
approaches.  Open bars represent wild-types and closed bars represent null muscles.  
Each column represents muscles from 5-6 mice, males or females, studied in 3-5 
independent experiments.  Comparisons were made between genotypes (*) and between 
time intervals or phases (#) with single symbols (*, #) representing P<0.05 and double 
symbols (**, ##) representing P<0.01. 
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Reciprocal effects on triglyceride and glucose oxidation 
 
 Considering the patterns observed with triglyceride synthesis and mobilization 
between the genotypes, we believed that at least a part of the mobilized triglycerides were 
oxidized, and therefore the null muscle should exhibit reduced triglyceride oxidation, in 
spite of the nature of the FABP mutation.  To verify this, we measured triglyceride 
oxidation (Figure 5) by counting the output of tritiated water (as previously described 
under Measurement of fatty acid oxidation in the methods [12]) in the Chase phase.  As a 
result, triglyceride oxidation was indeed considerably reduced in the null muscle, 
indicating that H-FABP is also required for efficient oxidation of internal triglycerides. 
 Using the same setup, we wanted to clarify whether or not glucose oxidation was 
influenced by our conditions (Figure 5).  As a result of pre-incubation for 2 hours in 1 
mM palmitate, the stimulatory effect on glucose oxidation in the null muscle that was 
observed after high-fat diet was demonstrated again even with mice fed standard chow 
diet.  Considering the pattern of triglyceride synthesis and mobilization noted earlier, we 
believe that we were able to mimic the observed effect of the high-fat diet, due to the 
increased synthesis, followed by the increased mobilization and oxidation.  We repeated 
the experiments with high-fat fed mice and obtained similar results, indicating the 
impaired synthesis, degradation, and oxidation of triglycerides in the null muscle. 
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Figure 5.  Triglyceride oxidation and glucose oxidation.  Open bars represent wild-types 
and closed bars represent null muscles.  Each column represents muscles from 5-6 mice, 
males or females, studied in 3-5 independent experiments.  Comparisons were made 
between genotypes (**) with P<0.01. 
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Glycolysis and glycogen synthesis 
 
 In the absence of insulin, the same genotypic pattern was observed with 
glycolysis (Figure 6) as with glucose oxidation, as the H-FABP null phenotype exhibited 
a slight decrease with respect to wild-type.  However, unlike oxidation, there was no 
significant difference between muscles incubated in the absence or in the presence of 1 
mM palmitate, indicating no acute effect of fatty acids.  In the presence of insulin, there 
was no genotypic difference in the absence of fatty acids, as was observed with uptake 
and oxidation.  However, unlike in the basal state, we did observe a significant reduction 
in the presence of 1 mM palmitate, indicating that the Randle cycle was observed only in 
the presence of insulin. 
 We measured glycogen synthesis (Figure 6) by counting the total 3H and 14C 
content of each muscle and normalizing to wet muscle weight.  We verified that insulin 
produces a much stronger effect on glycogen synthesis (3-4 fold) than on glycolysis or 
oxidation (1.5-2 fold), which was previously demonstrated in the literature.  However, 
there was no significant difference between genotypes or between muscles incubated in 
the absence or presence of palmitate, indicating that the Randle cycle does not operate on 
glycogen synthesis. 
 After high-fat diet (HFD), the null phenotype had significantly higher rates of 
glycolysis than the wild-type, both in the absence and presence of palmitate, as observed 
with glucose oxidation.  However, we did not observe an acute effect of palmitate in the 
absence or presence of insulin.  The results on glycogen synthesis after HFD were similar 
to those obtained after standard chow, as the dramatic effect of insulin remained, yet no 
acute effect of palmitate was observed. 
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Figure 6.  Glycolysis and glycogen synthesis.  Results are from standard chow (A, B) 
and high-fat diets (C, D) using wild-type (+/+) and H-FABP null (-/-) mice.  Each 
column represents muscles from 5-8 male mice, studied in 4-6 independent experiments.  
Open bars represent muscles incubated in the absence of fatty acids and closed bars 
represent incubation in the presence of 1 mM palmitate.  Comparisons were made 
between genotypes (*), between absence and presence of palmitate (#), and between 
absence and presence of insulin (+).  Single symbols (*, #) represent P<0.05 and double 
symbols (++) represent P<0.01. 
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Measurement of glucose oxidation with 2,4-dinitrophenol 
In order to determine whether or not the slight reduction of basal glucose 
oxidation in the null phenotype was due to a reduction in the oxidative capacity of the 
mitochondria, 2,4-dinitrophenol (DNP), an uncoupler of the electron transport chain 
known to maximize glucose oxidation to its full capacity, was used (Figure 7).  We 
verified the moderate decrease of oxidation in the null muscle, but in the presence of 
DNP, there was no longer any genotypic difference.  Hence, we concluded that the 
oxidative capacity of the mitochondria is not changed due to the mutation. 
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Figure 7.  Glucose oxidation with 2,4-dinitrophenol.  Comparison of wild-type (+/+) and 
H-FABP null (-/-) muscles in the absence (open bars) and presence of 2,4-dinitrophenol 
(closed bars).  Each column represents muscles from 5-6 male mice studied in 3-5 
independent experiments.  Comparisons were made between genotypes (*) and between 
absence and presence of DNP (+), with single symbols (*, +) representing P<0.05 and 
double symbols (++) representing P<0.01. 
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Measurement of pyruvate dehydrogenase (PDH) activity 
 
 It has been previously shown that an increase in fatty acid oxidation causes a 
decrease in glucose oxidation [47] via the inactivation (phosphorylation) of the pyruvate 
dehydrogenase (PDH) complex.  We did not obtain an increase in glucose oxidation after 
standard chow diet, but it was later obtained with high-fat diet.  We therefore 
hypothesized that since H-FABP null muscles after HFD exhibit dramatically reduced 
fatty acid oxidation and dramatically increased glucose oxidation, the in vivo activity of 
PDH should be significantly increased in the null as well.  Unexpectedly, however, we 
did not obtain a significant difference between the total or actual PDH activities between 
genotypes (Figure 8). 
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Figure 8.  Total and actual PDH activity.  The total (open bars) and actual (closed bars) 
PDH activity of wild-type (+/+) and H-FABP null (-/-) muscles.  Each column represents 
muscles from 5 male mice studied in 5 independent experiments.  Comparisons were 
made between total and actual activities (***) with P<0.001. 
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DISCUSSION 
 
 Our results provide us with new insights into the relationship between the 
regulation of fatty acid and glucose metabolism, as well as the role of H-FABP in their 
processes.  We have demonstrated that the acute effect of 1 mM palmitic acid inhibits 
glucose uptake and oxidation to a comparable degree regardless of whether or not H-
FABP was present.  This surprising discovery contradicted our initial hypothesis because 
the absence of H-FABP resulted in a massive (>50%) reduction in fatty acid oxidation.  
According to the Randle cycle, an increase in the oxidation of free fatty acids (FFA) 
inhibits glucose oxidation [47], presumably via the inactivation of pyruvate 
dehydrogenase (PDH).  Since fatty acid oxidation was significantly impaired in the null 
muscle, we would not have expected an inhibition of glucose oxidation to occur in the 
null muscle.  We have measured fatty acid oxidation at low and high concentrations (0.15 
and 1.5 mM palmitate) and the percent inhibition of oxidation due to the mutation was 
not significantly different between the two concentrations.  When comparing absolute 
values, however, both wild-type and null muscles exhibited increased fatty acid oxidation 
between 0.15 and 1.5 mM palmitic acid by a comparable degree, which may provide an 
explanation for why the acute effect on glucose oxidation was not different.  
Alternatively, a threshold concentration of palmitic acid may exist, at which the addition 
of more fatty acids will not affect glucose oxidation beyond a certain limit.  This 
hypothesis would require us to further examine the relationship between fatty acid 
concentration and glucose oxidation.  The palmitate-mediated decrease of glucose 
oxidation may also not require the entry of palmitate into cells, as fatty acid regulation 
through various cell surface receptors has been demonstrated in other tissues.  Since we 
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have also shown the acute inhibitory effect of fatty acids on glucose uptake with respect 
to both the wild-type and null, this mechanism is likely.  Nevertheless, we have 
demonstrated an effect of fatty acids on glucose metabolism that appears to operate 
independently of the H-FABP protein. 
 Secondly, we have demonstrated that an increase in glucose oxidation in the null 
muscle is associated with the impaired synthesis and mobilization of internal 
triglycerides.  Freshly isolated muscles from wild-type and null mice fed standard chow 
diet have been shown not to be significantly different with respect to triglyceride levels 
[5], yet impaired degradation in the null has been demonstrated during incubation at 0.5 
mM palmitic acid, a concentration known to allow triglyceride degradation.  Therefore, if 
triglyceride mobilization and oxidation is higher in wild-type muscles even after standard 
chow diet, one may ask why the Randle effect on glucose oxidation did not cause the 
switch in pattern between null and wild-type with respect to glucose oxidation in this 
situation.  We believe that a certain threshold amount of triglycerides is required to vastly 
suppress glucose oxidation in the wild-type, after its subsequent degradation and 
oxidation.  If there is a direct relationship between triglyceride content and rate of 
mobilization, then we can justify that the higher the triglyceride contect, the greater the 
rate of subsequent degradation and oxidation, and hence the greater the impact will be on 
glucose oxidation.  Furthermore, our measurements of total triglyceride levels before and 
after incubation without fatty acids are in excellent agreement with the rates of synthesis 
and breakdown, according to the radioactive tracer measurements.  Our results suggest 
that the inhibition of glucose oxidation through increased triglyceride oxidation is the 
principle mechanism of fatty acid regulation on glucose metabolism. 
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 We have also observed how the long-term (4 weeks) effects of administering a 
high-fat diet can be mimicked within such a short period of time (2 hours) after 
incubation in a high concentration of fatty acids.  If glucose metabolism is rapidly 
responsive to triglyceride levels, mobilization, and oxidation, we may have been able to 
obtain similar results after the administration of the high-fat diet for no more than a week, 
as plasma fatty acid concentrations are known to rise to high-fat steady state levels within 
a few days.  Furthermore, we have observed that isolated muscles from high-fat mice 
exhibited similar patterns in triglyceride accumulation, mobilization, and oxidation, 
compared to muscles isolated from mice fed standard chow.  We have also shown that the 
acute presence of palmitate suppresses glucose oxidation equally in both wild-type and 
null muscles, similar to the pattern observed after standard chow diet.  This indicates that 
the principal relationship between fatty acid and glucose metabolism remains the same, 
regardless of the diet. 
 Finally, the present study confirms our older result that unlike in heart where H-
FABP deficiency causes a marked increase in basal glucose oxidation, there is a moderate 
decrease of basal muscle glucose oxidation due to H-FABP deficiency after chow 
feeding.  It will require further experiments to determine the conditions that are optimal 
for either the inhibitory or the stimulatory effect of H-FABP on glucose oxidation and 
whether these effects can be completely dissociated.  We hypothesize that under 
conditions of high fuel competition and low triglyceride levels, the inhibitory effect of H-
FABP deficiency on muscle glucose oxidation prevails, while at nutritional abundance 
and high triglyceride levels, the stimulatory effect prevails.  In future experiments, we 
will need to determine how to vary the levels of fuel competition and triglycerides in 
 43
order to test our hypothesis.  We have also previously demonstrated that the stimulatory 
effect of H-FABP on glucose metabolism after high-fat diet is observed with glucose 
oxidation as well as glycolysis, but not glycogen synthesis.  Nevertheless, the total and 
actual pyruvate dehydrogenase (PDH) activity was not changed (Adhikari and Binas, 
unpubl. results).  This provides the suggestion that the mechanism of suppression acts on 
glucose oxidation, and that the result is not simply due to increased or decreased glucose 
uptake, as glycogen synthesis was not altered by the diet. 
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CONCLUSION 
 
 In summary, it is now clear that H-FABP deficiency affects muscle glucose 
oxidation both by reducing basal glucose oxidation and by increasing it (present study), 
with the balance depending on physiological circumstances.  Specifically, our results 
allow the hypothesis that H-FABP dependent muscle triglyceride mobilization, perhaps 
the oxidation of triglyceride-derived fatty acids, is a main factor counteracting muscle 
glucose oxidation.  The same H-FABP dependent relationship between glucose oxidation 
and triglyceride mobilization appears to be maintained under a chronic high-fat diet and 
thus contributes to the metabolic pattern that characterizes the pathogenesis of obesity 
and insulin resistance.  Finally, the present study also showed that the acute inhibitory 
effect of exogenous palmitate on skeletal muscle glucose oxidation is not disturbed by H-
FABP deficiency and hence fatty acid-dependent mechanisms exist that regulate muscle 
glucose oxidation without the involvement of H-FABP. 
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